Poliovirus Vaccine Inactivated

drug
On this page

Also known as Poliomyelitis vaccine

Summary

Poliovirus Vaccine Inactivated (CHEMBL2107962) is a phase-3 clinical-stage vaccine component; indicated across 7 conditions including viral infectious disease and poliomyelitis.

At a glance

  • Status: Max clinical phase 3 (not approved)
  • Modality: Vaccine component
  • Indications: 7 conditions
  • Clinical trials: 2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL2107962
NamePoliovirus Vaccine Inactivated
TypeVaccine component
Max phase3

Also known as: Poliomyelitis vaccine, Poliovirus vaccine inactivated, POLIOVIRUS VACCINE INACTIVATED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
viral infectious disease3MONDO:0005108EFO:0000763
poliomyelitis3MONDO:0017373EFO:0007450
Rotavirus infection3MONDO:0005194EFO:0002622
meningococcal infection3MONDO:0005373EFO:0004249
gastroenteritis3MONDO:0002269EFO:1001463
postpoliomyelitis syndrome2MONDO:0017416EFO:0007454
malaria1MONDO:0005136EFO:0001068

Clinical trials

Total trials: 2.

Phase distribution

PhaseTrials
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06397768PHASE3TERMINATEDCo-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
NCT01056705PHASE2COMPLETEDThe Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).